Celltrion's 'Omlyclo' Targets Japan's Pollen Allergy Market; Brokerages Raise Price Targets in Succession (BigGo) - Oct 23, 2026 - "Daol Investment & Securities raised its target to 290,000 won (approximately $220) from 280,000 won (approximately $210), while iM Securities set a target of 260,000 won (approximately $200). Omlyclo received approval in Japan in March for three indications—asthma, chronic urticaria, and seasonal allergic rhinitis—and is priced at about 70% of the original drug at the 150mg dose."
Biosimilar launch • Pricing • Allergic Rhinitis • Asthma • Chronic Spontaneous Urticaria • Immunology
|